Selected article for: "Charlson comorbidity index and study evaluate"

Author: Khalid, Imran; Yamani, Romaysaa M; Imran, Maryam; Akhtar, Muhammad Ali; Imran, Manahil; Gul, Rumaan; Khalid, Tabindeh Jabeen; Wali, Ghassan Y
Title: Comparison of characteristics and ventilatory course between coronavirus disease 2019 and Middle East respiratory syndrome patients with acute respiratory distress syndrome
  • Cord-id: h3gmqzxf
  • Document date: 2021_7_30
  • ID: h3gmqzxf
    Snippet: BACKGROUND: Both coronavirus disease 2019 (COVID-19) and Middle East respiratory syndrome (MERS) can cause acute respiratory distress syndrome (ARDS); however, their ARDS course and characteristics have not been compared, which we evaluate in our study. METHODS: MERS patients with ARDS seen during the 2014 outbreak and COVID-19 patients with ARDS admitted between March and December 2020 in our hospital were included, and their clinical characteristics, ventilatory course, and outcomes were compa
    Document: BACKGROUND: Both coronavirus disease 2019 (COVID-19) and Middle East respiratory syndrome (MERS) can cause acute respiratory distress syndrome (ARDS); however, their ARDS course and characteristics have not been compared, which we evaluate in our study. METHODS: MERS patients with ARDS seen during the 2014 outbreak and COVID-19 patients with ARDS admitted between March and December 2020 in our hospital were included, and their clinical characteristics, ventilatory course, and outcomes were compared. RESULTS: Forty-nine and 14 patients met the inclusion criteria for ARDS in the COVID-19 and MERS groups, respectively. Both groups had a median of four comorbidities with high Charlson comorbidity index value of 5 points (P>0.22). COVID-19 patients were older, obese, had significantly higher initial C-reactive protein (CRP), more likely to get trial of high-flow oxygen, and had delayed intubation (P≤0.04). The postintubation course was similar between the groups. Patients in both groups experienced a prolonged duration of mechanical ventilation, and majority received paralytics, dialysis, and vasopressor agents (P>0.28). The respiratory and ventilatory parameters after intubation (including tidal volume, fraction of inspired oxygen, peak and plateau pressures) and their progression over 3 weeks were similar (P>0.05). Rates of mortality in the ICU (53% vs. 64%) and hospital (59% vs. 64%) among COVID-19 and MERS patients (P≥0.54) were very high. CONCLUSIONS: Despite some distinctive differences between COVID-19 and MERS patients prior to intubation, the respiratory and ventilatory parameters postintubation were not different. The higher initial CRP level in COVID-19 patients may explain the steroid responsiveness in this population.

    Search related documents:
    Co phrase search for related documents
    • acid level and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • acid level and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acid level and lung compliance: 1
    • acid level and lung injury: 1, 2
    • acid level and lung tissue: 1
    • acute ards respiratory distress syndrome and low remain: 1
    • acute ards respiratory distress syndrome and lung alveolar damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • acute ards respiratory distress syndrome and lung compliance: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lung consolidation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute ards respiratory distress syndrome and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lung tissue damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute hypoxemic respiratory failure and lung compliance: 1
    • acute hypoxemic respiratory failure and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acute hypoxemic respiratory failure and lung tissue: 1, 2, 3
    • acute physiology and lung compliance: 1
    • acute physiology and lung injury: 1, 2, 3, 4, 5, 6, 7, 8
    • acute physiology and lung tissue: 1
    • acute respiratory syndrome and low remain: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14